Physician profile
Patsy H Mcclanahan
NPI 1275672909
$3,370.02
in general payments reported to CMS, 2019-2025
26 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what 97% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $382 · 2022: $130 · 2023: $856 · 2024: $910 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,857.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $349.11 | 2023-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $333.17 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Regeneron Healthcare Solutions, INC. | $227.08 | 2023-2024 | Dupixent |
| Genzyme Corporation | $200.02 | 2024 | |
| Novo Nordisk INC | $196.25 | 2024-2025 | Ozempic, Wegovy |
| Amgen INC. | $157.86 | 2025 | Otezla, Evenity |
| Glaxosmithkline, LLC. | $135.60 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $128.56 | 2025 | |
| Janssen Pharmaceuticals, INC | $127.38 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Alexion Pharmaceuticals, INC. | $125.00 | 2023 | Ultomiris |
| Insulet Corporation | $123.94 | 2025 | Omnipod |
| Abbvie INC. | $95.25 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $92.07 | 2025 | Intracept |
| Neurelis, INC. | $86.57 | 2023 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.00 | 2025 | Jardiance |
| Hologic Sales and Service, LLC | $82.20 | 2024 | Affirm Prone Biopsy System |
| Stryker Corporation | $81.82 | 2025 | |
| Dynavax Technologies Corporation | $80.83 | 2024 | Heplisav-B |
| Gilead Sciences, INC. | $80.79 | 2024 | Epclusa |
| Viiv Healthcare Company | $75.01 | 2021 | |
| Itamar Medical INC | $57.45 | 2023 | Watchpatone |
| Evofem Biosciences, INC. | $49.91 | 2022 | |
| Mayne Pharma Commercial LLC | $26.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patsy Mcclanahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.